PURPOSE: Paclitaxel is widely used for the treatment of patients with metastatic breast cancer (MBC). Although several mechanisms of paclitaxel resistance have been demonstrated, useful markers of paclitaxel resistance have not been available in clinical practice. METHODS: In this study, the clinical significance of tau expression in MBC cases was established by identifying candidates with paclitaxel administration. Tissue specimens obtained from 35 patients were examined. Status of tau expression was determined by immunohistochemistry. RESULTS: Fifteen cases were classified as tau-negative and 20 cases were classified as tau-positive, respectively. Sixty percent of tau-negative expression showed favorable response. Conversely, 85% of tau-positive expression showed progressive or stable disease after paclitaxel administration. Time to disease progression in tau-negative and tau-positive groups was 9.4 +/- 6.6 and 6.0 +/- 3.7 months, respectively. CONCLUSIONS: Patients with tau-positive expression may derive less benefit than tau-negative from paclitaxel therapy in MBC.
PURPOSE:Paclitaxel is widely used for the treatment of patients with metastatic breast cancer (MBC). Although several mechanisms of paclitaxel resistance have been demonstrated, useful markers of paclitaxel resistance have not been available in clinical practice. METHODS: In this study, the clinical significance of tau expression in MBC cases was established by identifying candidates with paclitaxel administration. Tissue specimens obtained from 35 patients were examined. Status of tau expression was determined by immunohistochemistry. RESULTS: Fifteen cases were classified as tau-negative and 20 cases were classified as tau-positive, respectively. Sixty percent of tau-negative expression showed favorable response. Conversely, 85% of tau-positive expression showed progressive or stable disease after paclitaxel administration. Time to disease progression in tau-negative and tau-positive groups was 9.4 +/- 6.6 and 6.0 +/- 3.7 months, respectively. CONCLUSIONS:Patients with tau-positive expression may derive less benefit than tau-negative from paclitaxel therapy in MBC.
Authors: Stephanie N Dorman; Katherina Baranova; Joan H M Knoll; Brad L Urquhart; Gabriella Mariani; Maria Luisa Carcangiu; Peter K Rogan Journal: Mol Oncol Date: 2015-08-22 Impact factor: 6.603
Authors: Al Muktafi Sadi; Dong-Yu Wang; Bruce J Youngson; Naomi Miller; Scott Boerner; Susan J Done; Wey L Leong Journal: BMC Cancer Date: 2011-06-16 Impact factor: 4.430
Authors: Maria T Baquero; Karen Lostritto; Mark D Gustavson; Kimberly A Bassi; Franck Appia; Robert L Camp; Annette M Molinaro; Lyndsay N Harris; David L Rimm Journal: Breast Cancer Res Date: 2011-11-02 Impact factor: 6.466